On September 16, 2015 Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally-driven diseases, reported the appointment of Lisa Taylor as Senior Vice President, Commercial Development (Press release, Tokai Pharmaceuticals, SEP 16, 2015, View Source;p=RssLanding&cat=news&id=2088218 [SID:1234507479]). Ms. Taylor brings over two decades of experience in biopharmaceutical marketing, and was a member of the launch team for Xtandi (enzalutamide) at Medivation, Inc.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At Tokai, Lisa will lead commercial preparedness for the launch of galeterone, a potential first-in-class Androgen Receptor Degrader. Tokai has commenced screening patients for the presence of the AR-V7 splice variant for enrollment in ARMOR3-SV, the company’s pivotal Phase 3 clinical trial of galeterone in men with metastatic castration-resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant. Top-line data from ARMOR3-SV are expected by the end of 2016.
"Lisa is an astute commercial strategist with deep expertise in prostate cancer, and we are thrilled to have her join Tokai’s management team," said Jodie Morrison, President and Chief Executive Officer of Tokai. "As we look ahead to results from our pivotal trial in late 2016 and prepare to commercialize galeterone, Lisa’s expertise and leadership will be critical to our successful delivery of this important therapeutic advance for men living with certain forms of advanced prostate cancer."
Most recently prior to joining Tokai, Ms. Taylor was the Principal and Founder of Packers Falls Group, Inc., a healthcare consulting firm that conducted commercial assessments and provided marketing and strategy consulting to biopharmaceutical companies. She previously served as Vice President, Commercial Development at Medivation, Inc., where she was the company’s first commercially-focused employee and subsequently served on the Xtandi (enzalutamide) launch team. Ms. Taylor began her career in strategy consulting at Booz, Allen and Hamilton and has held a number of strategic planning and marketing roles with in vitro diagnostic and medical device manufacturers. She is also an active patient advocate, serving on the Gynecologic Cancer Steering Committee’s Uterine Task Force at the National Cancer Institute and on the Developmental Therapeutics Committee of the Gynecologic Oncology Group.
"It is an honor to be joining Tokai at such an exciting time in the company’s growth," Ms. Taylor said. "We are developing a commercial strategy that builds from our differentiation as an Androgen Receptor Degrader with the potential to overcome the limitations seen with second-generation hormone therapies currently approved for CRPC. I look forward to applying my expertise in building a world-class commercial organization capable of effectively delivering galeterone to patients."